PharmaCorp RxTSXV:PCRX -1.96%36 EBIT per Share is C$-0.01 as of Mar. 2026. GuruFocus rates TSXV:PCRX with a GF Score™ of 36/100. The stock has 2 warning signs investors should review. Among 529 Healthcare Providers & Services companies, PharmaCorp Rx ranks better than 55.77% on this metric.
PharmaCorp Rx's EBIT per Share for the
three
months ended in Mar. 2026 was C$0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was C$-0.01.
During the past 3 years, the average EBIT per Share Growth Rate was 16.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for PharmaCorp Rx's EBIT per Share or its related term are showing as below:
TSXV:PCRX'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 16.2 Med: 16.2 Max: 16.2
Current: 16.2
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of PharmaCorp Rx was 16.20% per year. The lowest was 16.20% per year. And the median was 16.20% per year.
TSXV:PCRX's 3-Year EBIT Growth Rate is ranked better than 55.77% of 529
companies
in the Healthcare Providers & Services industry
Industry Median: 12.1
vs TSXV:PCRX: 16.20
PharmaCorp Rx's EBIT for the
three
months ended in Mar. 2026 was C$0.17 Mil.
PharmaCorp Rx (TSXV:PCRX) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
PharmaCorp Rx EBIT per Share Related Terms
PharmaCorp Rx EBIT per Share Historical Data
* Premium members only.
The historical data trend for PharmaCorp Rx's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaCorp Rx (TSXV:PCRX) has a EBIT per Share of C$-0.01 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on PharmaCorp Rx and its competitors. According to the industry distribution chart, PharmaCorp Rx ranks #234 out of 529 companies in the Healthcare Providers & Services industry, placing it in the top 44.2%.
Is PharmaCorp Rx's EBIT per Share too high?
PharmaCorp Rx's current EBIT per Share is C$-0.01. Based on the distribution chart, PharmaCorp Rx ranks #234 out of 529 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, PharmaCorp Rx has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCorp Rx's EBIT per Share compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, PharmaCorp Rx ranks #234 out of 529 companies for EBIT per Share. This puts PharmaCorp Rx in the upper half of its industry. The industry median EBIT per Share is 12.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 12.10, based on 529 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on PharmaCorp Rx and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 12.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaCorp Rx's current EBIT per Share is C$-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCorp Rx stock overvalued right now?
PharmaCorp Rx (TSXV:PCRX) has a current EBIT per Share of C$-0.01. The current EBIT per Share is C$-0.01. PharmaCorp Rx's overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For PharmaCorp Rx (TSXV:PCRX), the current EBIT per Share is C$-0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PharmaCorp Rx Inc operates three PharmaChoice bannered pharmacies in Canada and will continue to acquire PharmaChoice Canada-branded pharmacies as it come to market in conjunction with its strategic alliance agreement with PharmaChoice Canada. The company will also acquire independently owned non-PharmaChoice Canada-bannered pharmacies in Canada, and thereafter, continue to operate such acquired pharmacies under a PharmaChoice Canada banner.
36GF Score
Get the complete analysis for TSXV:PCRX
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:PCRX has been successfully added to your 
